The presence of sarcopenia before lung resection surgery might be an important factor of short-term and long-term prognosis in lung cancer patients. Through this study, investigators plan to demonstrate evidence whether sarcopenia is a useful clinical biomarker for risk stratification in elderly patients undergoing lung cancer surgery.
Eligibility
Sex
ALL
Min age
70 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients planning to perform curative surgery for confirmed lung cancer and pulmonary nodules suspected for lung cancer
* Patients or legal representatives who could understand and write written consent prior to the initiation of the clinical trial and are able to comply with the requirements for the clinical trial
Exclusion Criteria:
* Patients with treatment history for lung cancer or other solid cancer within 5 years (except patients with adenocarcinoma in situ for lung cancer)
* Patients who need simultaneous surgery with lung caner surgery for other accompanying diseases
* Patients who are not eligible to participate in the study judged by the researcher
Primary outcome measure(s)
overall survival — 5 years after the day of lung cancer surgery survival status during the follow-up after the lung cancer surgery
Trial sites (1)
Facility
City
Region
Status
Seoul National University Hospital
Seoul
South Korea
More Seoul National University Hospital trials in South Korea
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.